Please ensure Javascript is enabled for purposes of website accessibility

CVS Is in the Zone

By Timothy M. Otte – Updated Apr 5, 2017 at 5:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmacy giant grew EPS by 36% in the third quarter.

Ever remember a time when everything you touched turned to gold? Like Starbucks during the 1990s, Apple since it discovered the iPod, or Google since it became Google. It's like some companies get in a "zone" where they just can't miss.

CVS Caremark (NYSE:CVS) has been in that "zone" ever since CVS tied the knot with Caremark last year. The synergies between selling prescriptions, helping customers manage their benefits, and getting a few extra items thrown in the shopping cart are looking more and more irresistable.

The company proved once again it's no sicko by posting third-quarter sales that increased 83% compared to last year, to $20.5 billion. Comparable-store sales were up 5%, with the script business contributing 4.3%, and the front end adding 6.5%. Operating margins expanded 140 basis points. Gross margins in the PBM segment were up 130 b.p. and increased 160 b.p. in the retail segment. Diluted earnings per share jumped 37% to $0.45, beating Street expectations by a penny.

CVS has been on a roll over the past nine months, with sales up 71% and earnnigs per share up 22%. Investors have noticed the stellar performance and have boosted the stock 25% higher since the beginning of the year.

In the conference call, president and CEO Tom Ryan described it as a "measured, evolutionary process that will continue to pick up steam in '08 and beyond." The company is adding Minute Clinics into the retail stores as fast as it can. Since last quarter, CVS has contracted an additional $600 million in new businesses for 2008, a combination of PBM and Medicare Part D. Even the Save-on and Osco stores acquired from Albertsons last year are showing sales and margin improvements.

It's not like competitors aren't trying to take a share of this market. Wal-Mart (NYSE:WMT) continues to lower prescription prices, and Walgreen (NYSE:WAG) is building stores like crazy. But I think CVS has a competitive advantage in the number and quality of "touch-points" it has with the prescription-consuming customer. As long as CVS can provide the best service to this rapidly growing customer base, it appears unstoppable in the near term.

Catch up on the pharmacy market with:

Fool contributor Timothy M. Otte surveys the retail scene from Dallas. He welcomes comments on his articles, and owns shares of Wal-Mart, but none of the other companies mentioned in this article. Wal-Mart is an Inside Value pick. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$98.35 (-1.48%) $-1.48
Walmart Stock Quote
Walmart
WMT
$130.06 (-2.50%) $-3.33
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.83 (-1.47%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.